Latest Organofluorides Stories
RALEIGH, N.C., Jan. 6, 2015 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Cindy Whitehead has been named CEO, effective immediately.
NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer.
The Firm is actively filing Risperdal gynecomastia claims in the Philadelphia proceeding, all of which allege that the medication caused men and boys to experience excessive breast growth.
ReportsnReports.com adds "Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023" to its store.
RnRMarketResearch.com adds “TS-1 (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
The Firm is actively filing Risperdal lawsuits in this proceeding on behalf of men and boys who allegedly developed gynecomastia due to its use. New York, New
DUBLIN, Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the Company has received a complete response letter from the U.S.
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
The Firm is currently representing numerous men and boys in Risperdal lawsuits that also allege the drug caused gynecomastia, a condition marked by the excessive breast growth in male patients.
The Firm is representing numerous men and boys in Risperdal lawsuits, all of whom allegedly developed gynecomastia (male breast growth) due to an elevation of prolactin caused by Risperdal.